Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

1134669

	registered interest
	date	25/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Abortion
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether there are any circumstances in which a pregnancy that does not (1) pose a risk to the physical health of a mother, and (2) involve a foetus that has been diagnosed with a disability, can be involuntarily terminated.
	tabling member printed	Lord Alton of Liverpool
	uin	HL16636
	answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>A decision to terminate a pregnancy must comply with the legal requirements of the Abortion Act 1967. In circumstances where a person lacks capacity, the courts have the authority to make serious healthcare and treatment decisions, in the best interests of the person and pursuant to the Mental Capacity Act 2005, and this could include whether a pregnancy should be terminated.</p> answering member printed Baroness Blackwood of North Oxford question first answered 05/07/2019 10:55:39 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	738 label Biography information for Lord Alton of Liverpool

1134679

	registered interest
	date	25/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Self-harm: Children
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what specific measures they are taking to prevent self-harming in very young children.
	tabling member printed	Baroness D'Souza
	uin	HL16646
	answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>The Government is committed to preventing self-harm among children and young people of all ages. In 2017 Public Health England introduced the Rise Above programme that offers advice to young people on dealing with difficult emotions and situations that can lead to problems such as stress, bullying and self-harm.</p><p>The current Healthy Child Programme (from 0-5 years old) aims to support early identification of problems with an emphasis on support for mothers and fathers or partners to provide sensitive and attuned parenting.</p><p>On 17 June 2019, it was announced that tailored advice will be provided to parents on supporting their children’s mental health and well-being by 2020 through the ‘Every Mind Matters’ campaign. This will include information on subjects such as stress, screen time, online bullying, body image and self-harm.</p><p>Ministers wrote to social media and internet providers on 26 January to express concern about suicide and self-harm content. The companies have committed to increasing their efforts by establishing and funding a strategic partnership with the Samaritans to tackle this content and support vulnerable users of their platforms.</p> answering member printed Baroness Blackwood of North Oxford question first answered 05/07/2019 10:55:15 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3709 label Biography information for Baroness D'Souza

1134691

	registered interest
	date	25/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment: Overseas Trade
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what practical steps they are taking to ensure the continued import and export of continence products and similar medical devices in the event of a no-deal Brexit.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16658
	answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>As in preparation for 29 March and 12 April, our contingency plans for 31 October will cover the National Health Service, social care and the independent sector and covers all medicines, medical devices and clinical consumables, supplies for clinical trials, vaccines and countermeasures, and organs and tissues for transplants.</p><p>The Department has continued to work closely with the devolved administrations, industry trade bodies and suppliers, the NHS and other key stakeholders. Prior to 29 March, the Department analysed the supply chains of 12,300 medicines, close to half a million product lines of medical devices and clinical consumables, vaccines used in national and local programmes, and essential non-clinical goods on which the health and care system relies. These analyses and assessments have been updated where necessary and will continue to be refined while a ‘no deal’ European Union exit remains a possibility. This work has informed our plans.</p><p>We are asking suppliers to analyse their supply chains and to make alternative plans if they anticipate disruption, including rerouting to alternative ports or using airfreight where necessary. Our contingency measures aim to support industry-led measures and, where required, act as a ‘last resort’ to be used only when a supplier’s alternative arrangements encounter difficulties, to ensure uninterrupted supply.</p><p>While we never give guarantees, we are confident that, if everyone – including suppliers, freight companies, international partners and the health and care system – does what they need to do, the supply of medicines and medical products should be uninterrupted in the event of a ‘no deal’ EU exit.</p><p><strong> </strong></p> answering member printed Baroness Blackwood of North Oxford question first answered 05/07/2019 10:57:58 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1134692

	registered interest
	date	25/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Procurement
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what role has recently been played by Deloitte, and at what cost, in the development by NHS Improvement of proposals to introduce a centralised NHS procurement system for products and services; and what steps are being taken to ensure that the introduction of such a system does not restrict medical practitioners from prescribing any continence product on the Medicines Tariff that they consider to be the most appropriate product for individual patients.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16659
	answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>NHS Improvement, through an open and competitive procurement process, awarded Deloitte a contract to support NHS Improvement to develop a new NHS Procurement Target Operating Model. The contract for phase 1 of this work, which ended on 31 May 2019, cost £400,000.</p><p>The new Procurement Target Operating Model will consider the processes, data and skills and capabilities to deliver a more efficient procurement service. The remit of the Procurement Target Operating Model programme does not cover clinical products and therefore were not considered as part of this review. NHS Improvement has collaborated with National Health Service providers’ chief executives, finance and procurement leads to develop the NHS’s procurement target operating model. Members of the Healthcare Supply Association have also been engaged with as part of the target operating model’s development.</p><p>Clinical products, including continence products, which are procured by the NHS are the remit of Supply Chain Coordination Limited who work with NHS providers’ procurement teams across England. Clinical product suppliers have not been engaged with on the new procurement target operating model as they are outside its remit.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16660 question first answered 05/07/2019 10:57:17 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1134693

	registered interest
	date	25/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Procurement
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they have consulted (1) the Health Care Supply Association, (2) the Urology Trade Association, and (3) organisations representing patients who use continence products, about the development by NHS Improvement of proposals to introduce a centralised NHS procurement system for products and services; and if not, why not.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16660
	answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>NHS Improvement, through an open and competitive procurement process, awarded Deloitte a contract to support NHS Improvement to develop a new NHS Procurement Target Operating Model. The contract for phase 1 of this work, which ended on 31 May 2019, cost £400,000.</p><p>The new Procurement Target Operating Model will consider the processes, data and skills and capabilities to deliver a more efficient procurement service. The remit of the Procurement Target Operating Model programme does not cover clinical products and therefore were not considered as part of this review. NHS Improvement has collaborated with National Health Service providers’ chief executives, finance and procurement leads to develop the NHS’s procurement target operating model. Members of the Healthcare Supply Association have also been engaged with as part of the target operating model’s development.</p><p>Clinical products, including continence products, which are procured by the NHS are the remit of Supply Chain Coordination Limited who work with NHS providers’ procurement teams across England. Clinical product suppliers have not been engaged with on the new procurement target operating model as they are outside its remit.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16659 question first answered 05/07/2019 10:57:17 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1134710

	registered interest
	date	25/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Obesity: Children
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the impact of Brexit on measures to tackle child obesity.
	tabling member printed	Lord Taylor of Warwick
	uin	HL16677
	answer	answer is ministerial correction date of answer 09/07/2019 answer text <p>As a responsible Government, we have been planning for all eventualities and that includes managing the impacts of a ‘no deal’ European Union exit.</p><p>Following the publication of our world leading strategy <em>Childhood Obesity: a plan for action</em> in 2016 and <em>Childhood Obesity: a plan for action, Chapter 2,</em> significant progress has been made. Since the publication of the 2016 plan, half of all drinks in scope of the soft drinks industry levy are being reformulated, some products in the sugar production programme are exceeding their first year target, and significant investments are being made in schools to promote physical activity and healthy eating.</p><p>Consultations have been conducted on a number of policy areas from Chapter 2 and our responses to those will be set out later this year. As we have received thousands of responses to these consultations it is important we take the time to consider them carefully before we take action on this important issue.</p> answering member printed Baroness Blackwood of North Oxford question first answered 09/07/2019 13:38:27 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1796 label Biography information for Lord Taylor of Warwick

1135065

	registered interest
	date	26/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bacterial Diseases
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 4 June (HL15832), what assessment they have made of (1) the future costs to the NHS as a result of the spread of carbapenem-resistant Enterobacteriaceae, (2) the costs of new measures introduced in 2019 specifically to prevent the transmission of such Enterobacteriaceae, and (3) the views of infection control nurses on investment to prevent the transmission of such Enterobacteriaceae.
	tabling member printed	Baroness Gardner of Parkes
	uin	HL16692
	answer	answer is ministerial correction date of answer 09/07/2019 answer text <p>Public Health England (PHE) has predicted future spread and the health and cost impact to the National Health Service of the Enterobacteriaceae Escherichia coli and a national outbreak of a highly-resistant organism, reflecting carbapenem-resistant Enterobacteriaceae. The models used in this assessment are published in the paper <em>A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation Study</em>. A copy of the paper is attached.</p><p>Such predictions are highly uncertain. There remain unknowns regarding transmission, efficacy of interventions and the additional hospital stay for infected patients (constituting a large part of the cost to the NHS).</p><p>PHE has worked with NHS colleagues, estimating the cost of controlling a carbapenemase-producing Enterobacteriaceae (CPE) outbreak in five London hospitals to be over £1 million. Monitoring costs alongside implementation of PHE’s upcoming update of the CPE toolkit for health and social care is an important component of enabling cost-effectiveness evaluation.</p><p>Staff interviewed about the challenges of implementing the existing CPE toolkit highlighted maintaining awareness and training as key challenges, alongside infection prevention resourcing. An analysis of the responses was published in the paper <em>An evaluation of a toolkit for the early detection, management, and control of carbapenemase-producing Enterobacteriaceae: a survey of acute hospital trusts in England</em>. A copy is attached.</p> answering member printed Baroness Blackwood of North Oxford attachment 1 file name A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK.pdf title Risk Assessment of Antibiotic Pan Drug Resistance 2 file name An evaluation of a toolkit for the early detection management and control of carbapenemase-producing Enterobacteriaceae. A survey of acute hospital .pdf title An evaluation of a toolkit question first answered 09/07/2019 13:34:21 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3596 label Biography information for Baroness Gardner of Parkes

1135071

	registered interest
	date	26/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Migrant Workers
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what recent assessment they have made of the impact on the ability of the NHS to recruit experienced staff from the EU of the UK leaving the EU without a deal; and what plans they have to make up any shortfall in numbers of staff.
	tabling member printed	Lord Jones of Cheltenham
	uin	HL16698
	answer	answer is ministerial correction date of answer 09/07/2019 answer text <p>The Government recognises the need for the National Health Service to be able to recruit effectively from abroad and the Immigration White Paper, <em>The UK’s future skills-based immigration system</em>, published in December 2018, sets out the foundation for a single immigration system, where it is workers’ skills that matter, not where they come from.</p><p>The Government has taken steps to ensure that European Union citizens can continue to come and work in the NHS once we have left the EU. In March 2019, we put in place legislation that ensures the continued recognition of qualifications from EU countries by all professional regulators covering the health and social care sectors. This means that EU citizens will continue to be able to come and practice in the United Kingdom once we have left the EU, even if we leave without a ‘deal’.</p><p>The NHS Long Term Plan and interim People Plan have both set out a vital strategic framework to ensure that over the next 10 years the NHS will have the staff it needs so that nurses and doctors have the time they need to care, working in a supportive culture that allows them to provide the expert compassionate care they are committed to providing. The interim People Plan sets out how part of this will be made up from an expansion of international recruitment of NHS staff.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 09/07/2019 12:38:48 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	248 label Biography information for Lord Jones of Cheltenham

1135097

	registered interest
	date	26/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: EU Law
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they have taken to assess the impact on the NHS of leaving the European regulatory framework in the event of a no-deal Brexit.
	tabling member printed	Lord Taylor of Warwick
	uin	HL16724
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The Government maintains that leaving the European Union with a deal is the best outcome. However, as a responsible Government, we continue to plan and prepare for all eventualities, including a potential ‘no deal’ exit.</p><p>The Government is committed to the safe and effective regulation of medicines and medical devices in the United Kingdom. We will continue to strengthen safety while ensuring National Health Service patients and the public have fast access to new, innovative medicines.</p><p>The Government is providing short-term regulatory flexibility, in order to ensure that the UK can still import medicines from the European Economic Area (EEA), when the UK leaves the EU. We have announced that, in the event of a ‘no deal’ scenario, the UK will recognise batch testing that takes place in the EU and EEA, thus ensuring regulatory continuity so that the NHS can maintain ease of access to medicines developed and manufactured in the EU.</p><p>In the event of a ‘no deal’ exit, the Government will continue to ensure that UK patients are able to access the best and most innovative treatments and that their safety is protected.</p> answering member printed Baroness Blackwood of North Oxford question first answered 10/07/2019 15:07:17 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1796 label Biography information for Lord Taylor of Warwick

1135412

	registered interest
	date	27/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	IVF: Breast Cancer
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answers by the Parliamentary Under-Secretary of State for Health on 14 July 2014 (HC Deb, col 448W), Earl Howe on 3 December 2014 (HL273), Lord O'Shaughnessy on 3 December 2018 (HL11600), and comments by the Parliamentary Under-Secretary of State for Health on 20 January 2016 (HC Deb, col 623WH), to what extent the Human Fertilisation and Embryology Authority (HFEA) database is linked to (1) NHS databases, and (2) cancer registries; whether data from the register of patients and treatments that is maintained by the HFEA is sufficient to assess the contention that IVF in older women linked to an increased risk of breast cancer; and how the HFEA will ensure that information provided to patients regarding any potential long-term safety implications associated with treatment will include appropriate reference to such risks.
	tabling member printed	Lord Alton of Liverpool
	uin	HL16733
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) Register is not linked to any National Health Service databases or cancer registries; and data from the Register alone would not allow an assessment of the risk to be identified. However, under the Human Fertilisation and Embryology Act (Disclosure of Information for Research Purposes) Regulations 2010, the HFEA may authorise the processing of disclosable protected information contained in the Register for research, in the public interest or in the interests of improving patient care. A recent study by University College London investigated risks of ovarian, breast, and corpus uteri cancer in women treated with Assisted Reproductive Technologies and found no link between the use of ovarian stimulatory drugs and an increased risk of cancer.</p><p>The HFEA continually updates patient information whenever new clinical information is available. The HFEA is advised by the Scientific and Clinical Advances Advisory Committee on scientific and clinical developments (including research) in assisted conception, embryo research and related areas.</p> answering member printed Baroness Blackwood of North Oxford question first answered 10/07/2019 15:08:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	738 label Biography information for Lord Alton of Liverpool